KATHMANDU, Jan 20: The Department of Drug Administration has suspended the sale of calcium tablets produced by Currex Arya Pharmaceuticals, located in Banepa, Kavre. The decision follows the discovery of defects in the 500 mg calcium and Vitamin D3 tablets which were sold under the brand name ‘Calbone.’
Related story
Vitamin 'A' and de-worming tablets being administered to childr...
The batch number TCL-229 was tested at the National Medicine Laboratory. It was found to be of substandard quality. As a result, the department has instructed the manufacturing company to stop the distribution of this batch and retrieve the products from the market.
The department has also advised against recommending or using the defective batch of tablets.
